Literature DB >> 6202767

Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line.

K Yoshizaki, T Nakagawa, K Fukunaga, L T Tseng, Y Yamamura, T Kishimoto.   

Abstract

A subclone of a human B lymphoblastoid cell line, CESS-2, spontaneously secreted a kind of BCDF (B-BCDF) in their culture supernatant without any stimulation. B-BCDF induced IgG and IgM secretions in human B lymphoblastoid cell lines, CESS cells and CL-4 cells, respectively. BCDF-responsive CESS cells expressed IgG on their surface, whereas CESS-2, which were able to secrete B-BCDF, did not express surface IgG. B-BCDF could induce Ig-secretion in SAC-stimulated low density peripheral B cells, but did not induce Ig secretion in nonstimulated B cells. B-BCDF did not show any IL 2, BCGF, or gamma-interferon activities. B-BCDF was highly purified by gel filtration on an AcA-34 column, by chromatofocusing and ion exchange chromatography on an HPLC system, and by gel filtration on an HPLC column. Highly purified preparations showed a single protein band in SDS-PAGE analysis. The m.w. and isoelectric points of the factor were 20,000 and pH 5.1 to 5.2, respectively. The minimum protein amount required for Ig induction in B cell lines was 16 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202767

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Purification and some properties of proliferation suppressing factor from human lung adenocarcinoma PC-8.

Authors:  H Shinmoto; S Dosako; K Yamada; S Shirahata; H Murakami
Journal:  Cytotechnology       Date:  1990-09       Impact factor: 2.058

2.  IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production.

Authors:  Kenichiro Maeda; Harshini Mehta; Douglas A Drevets; K Mark Coggeshall
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

3.  IgA specific helper factor (alpha HF) in human colostrum.

Authors:  H Shinmoto; H Kawakami; S Dosako; Y Sogo
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

Review 4.  Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Authors:  Charli Dominguez; Justin M David; Claudia Palena
Journal:  Semin Cancer Biol       Date:  2017-08-18       Impact factor: 15.707

Review 5.  IL-6 as a keystone cytokine in health and disease.

Authors:  Christopher A Hunter; Simon A Jones
Journal:  Nat Immunol       Date:  2015-05       Impact factor: 25.606

Review 6.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

8.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.

Authors:  Sang-Hoon Sin; Sun Ah Kang; Yongbaek Kim; Anthony Eason; Kelly Tan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

Review 9.  Tocilizumab in pediatric rheumatology: the clinical experience.

Authors:  Reut Gurion; Nora G Singer
Journal:  Curr Rheumatol Rep       Date:  2013-07       Impact factor: 4.592

10.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

Authors:  T Hirano; T Taga; N Nakano; K Yasukawa; S Kashiwamura; K Shimizu; K Nakajima; K H Pyun; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.